Jonas Ekblom appointed new Pergamum CEO

STOCKHOLM - October 28, 2010. Jonas Ekblom has been appointed as new Chief Executive Officer of Pergamum AB, the dermatology and wound healing company in the Karolinska Development portfolio, from November 1, 2010.

" We are delighted to have attracted Jonas Ekblom, who with his vast experience from pharmaceutical development will be able to contribute to a continuous strong development of Pergamum and its programs. Pergamum is a unique biotech company dedicated to the development of new, innovative treatments within dermatology and wound healing. Currently, we have a number of promising pre-clinical projects and three progams undergoing clinical trials" said Jörgen Thorball, chairman of the board Pergamum AB.

"There is a need for new business models for research and development within the biotech sector. Pergamum works in a new way; having several companies or programs within the same therapeutic area in the same organization and using this to its advantage by offering resources that smaller organizations normally don't have access to, while at the same time securing the entrepreneurial spirit needed to drive programs efficiently. I am delighted to take on this role within Pergamum, says Jonas Ekblom.

Jonas Ekblom has more than 15 years experience from leading positions in big and small pharmaceutical companies mainly in Sweden and the USA. Most recently, he has served as CEO at Bows Pharmaceuticals AG, which is a Swiss biotech company. Before that he was working in the US for several companies, including serving as head of Invitrogen's project organization between 2005 and 2008. He is also on the board of the humanitarian non-profit organization "The Releef Initiative" focused on product development to fulfill unmet needs in under-served areas.

For further information, please contact:

Jörgen Thorball, Chairman of the Board, Pergamum AB
Tel: +46 8-524 891 00, e-mail: jorgen.thorball@pergamum.com

TO THE EDITORS

About Pergamum´
Pergamum is a biopharmaceutical company specialized in dermatology and wound healing. Within Pergamum, companies and projects are managed as fully integrated operating units with access to a core team of experienced professionals within drug development and business management. This model provides Pergamum with an attractive diversified product pipeline, while minimizing development cost and time-to-market and risk. Three programs are currently in clinical phase. www.pergamum.com

About Karolinska Development
Karolinska Development manages one of the largest portfolios of life science companies in Europe. Using a unique business model, the company cost efficiently guides the commercialization of world class life science innovations. Since its inception in 2003, Karolinska Development has built a portfolio of some 40 companies. Among the company's projects, 12 candidate drugs are undergoing clinical trials and it is estimated that more than 20 substances have first-in-class potential. www.karolinskadevelopment.com